Bio-Techne on Monday announced it has filed a patent infringement lawsuit against Molecular Instruments in the U.K. to enforce Bio-Techne’s intellectual property for its RNAscope in situ hybridization (ISH) technology in spatial biology and clinical applications.
Bio-Techne alleged that Molecular Instruments' HCR 3.0 technology infringes on Bio-Techne's European Patents (U.K.) 2,500,439 and 1,910,572 for the RNAscope ISH technology.
Bio-Techne's Advanced Cell Diagnostics business owns the patents that cover various features of the RNAscope technology, which is used in spatial biology and clinical applications.
The lawsuit seeks damages and injunctive relief and aims to require that Molecular Instruments ceases infringement in the U.K., Bio-Techne said.
"Bio-Techne has made substantial investments in the development and application of its RNAscope technology to advance research discovery and accelerate diagnostic and therapeutic product development," Chuck Kummeth, president and CEO of Bio-Techne, said in a statement. "Our intellectual property portfolio is foundational to our innovation in the spatial biology detection space, and we are committed to protecting these investments and defending our intellectual property rights."